Gemifloxacin is a fluoroquinolone antibiotic that displays antibacterial activity against both gram positive and gram negative bacteria. Gemifloxacin is commonly used as a short course of treatment for acute exacerbations of chronic bronchitis and COPD. This compound is also an effective treatment for Streptococcus pneumoniae-induced community-acquired pneumonia.
| Cas No. | 210353-53-0 |
|---|---|
| Purity | ≥98% |
| Formula | C18H20FN5O4 • CH3SO3H |
| Formula Wt. | 485.49 |
| IUPAC Name | 7-[(4Z)-3-(aminomethyl)-4-methoxyiminopyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid;methanesulfonic acid |
| Appearance | Off white to yellowish powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| MSDS | G1849 MSDS PDF |
|---|---|
| Info Sheet | G1849 Info Sheet PDF |
Anzueto A, Miravitlles M. Short-course fluoroquinolone therapy in exacerbations of chronic bronchitis and COPD. Respir Med. 2010 Oct;104(10):1396-403. PMID: 20580215.
Lode HM, Schmidt-Ionas M, Stahlmann R. Gemifloxacin for community-acquired pneumonia. Expert Opin Investig Drugs. 2008 May;17(5):779-86. PMID: 18447602.
Bhavnani SM, Andes DR. Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy. 2005 May;25(5):717-40. PMID: 15899734.
